Christine Klein

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8187497/publications.pdf

Version: 2024-02-01

155 papers	14,368 citations	53794 45 h-index	22832 112 g-index
164 all docs	164 docs citations	164 times ranked	13218 citing authors

#	Article	IF	Citations
1	Mosaic divergent repeat interruptions in XDP influence repeat stability and disease onset. Brain, 2023, 146, 1075-1082.	7.6	10
2	Parkinson's Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by <scp>2â€Hydroxypropylâ€Î²â€Cyclodextrin</scp> Treatment. Movement Disorders, 2022, 37, 80-94.	3.9	37
3	Glucocerebrosidase (GBA) gene variants in a multi-ethnic Asian cohort with Parkinsonâ€™s disease: mutational spectrum and clinical features. Journal of Neural Transmission, 2022, 129, 37-48.	2.8	18
4	A mixed-ethnicity myoclonus-dystonia patient with a novel SGCE nonsense mutation: a case report. BMC Neurology, 2022, 22, 11.	1.8	0
5	Elucidating Hexanucleotide Repeat Number and Methylation within the X-Linked Dystonia-Parkinsonism (XDP)-Related SVA Retrotransposon in TAF1 with Nanopore Sequencing. Genes, 2022, 13, 126.	2.4	9
6	Ceramide-induced mitophagy impairs ÃŸ-oxidation-linked energy production in PINK1 deficiency. Autophagy, 2022, 18, 703-704.	9.1	5
7	Multiâ€omic landscaping of human midbrains identifies diseaseâ€relevant molecular targets and pathways in advancedâ€stage Parkinson's disease. Clinical and Translational Medicine, 2022, 12, e692.	4.0	22
8	Transcriptional Alterations in X-Linked Dystoniaâ€“Parkinsonism Caused by the SVA Retrotransposon. International Journal of Molecular Sciences, 2022, 23, 2231.	4.1	6
9	Coffee, smoking and aspirin are associated with age at onset in idiopathic Parkinsonâ€™s disease. Journal of Neurology, 2022, 269, 4195-4203.	3.6	11
10	Relationship of Genotype, Phenotype, and Treatment in Dopaâ€Responsive Dystonia: <scp>MDSGene</scp> Review. Movement Disorders, 2022, 37, 237-252.	3.9	19
11	One-year surveillance of SARS-CoV-2 transmission of the ELISA cohort: A model for population-based monitoring of infection risk. Science Advances, 2022, 8, eabm5016.	10.3	14
12	Parkin Deficiency Impairs Mitochondrial <scp>DNA</scp> Dynamics and Propagates Inflammation. Movement Disorders, 2022, 37, 1405-1415.	3.9	28
13	Pronounced Orthostatic Hypotension in GBA-Related Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, 1539-1544.	2.8	4
14	Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force â€“ An Update. Movement Disorders, 2022, 37, 905-935.	3.9	49
15	Prodromal Xâ€Linked Dystoniaâ€Parkinsonism is Characterized by a Subclinical Motor Phenotype. Movement Disorders, 2022, 37, 1474-1482.	3.9	7
16	A Mendelian randomization study investigating the causal role of inflammation on Parkinsonâ€™s disease. Brain, 2022, 145, 3444-3453.	7.6	26
17	Protocol of the Luebeck longitudinal investigation of SARS-CoV-2 infection (ELISA) study â€“ a prospective population-based cohort study. BMC Public Health, 2022, 22, .	2.9	3
18	Genetic Testing for Parkinson Disease. Neurology: Clinical Practice, 2021, 11, 69-77.	1.6	24

#	Article	IF	Citations
19	Mitochondria and Parkinsonâ€™s Disease: Clinical, Molecular, and Translational Aspects. Journal of Parkinson's Disease, 2021, 11, 45-60.	2.8	100
20	Genetic Risk of Alzheimer's Disease â€“ Sleepless with the Enemy. Annals of Neurology, 2021, 89, 27-29.	5.3	0
21	Dystonia and Tremor. Neurology, 2021, 96, e563-e574.	1.1	46
22	First Case of <scp>Parkinsonianâ€Pyramidal</scp> Syndrome Associated with a <scp>TBK1</scp> Mutation. Movement Disorders, 2021, 36, 523-525.	3.9	2
23	<scp>EIF2AK2</scp> Missense Variants Associated with Early Onset Generalized Dystonia. Annals of Neurology, 2021, 89, 485-497.	5.3	32
24	Monogenic Causes of Dystonic Syndromes: Common in Dystonic Cerebral Palsy, Rare in Isolated Dystonia. Movement Disorders, 2021, 36, 84-84.	3.9	1
25	Truncating <scp>VPS16</scp> Mutations Are Rare in Early Onset Dystonia. Annals of Neurology, 2021, 89, 625-626.	5.3	14
26	Genetic and Environmental Factors in <scp>P</scp>arkinson's Disease Converge on Immune Function and Inflammation. Movement Disorders, 2021, 36, 25-36.	3.9	69
27	The Rostock International Parkinson's Disease (<scp>ROPAD</scp>) Study: Protocol and Initial Findings. Movement Disorders, 2021, 36, 1005-1010.	3.9	50
28	Discordant Monozygotic Parkinson Disease Twins: Role of Mitochondrial Integrity. Annals of Neurology, 2021, 89, 158-164.	5.3	10
29	Parkin Deficiency Appears Not to Be Associated with Cardiac Damage in Parkinson's Disease. Movement Disorders, 2021, 36, 271-273.	3.9	4
30	Induced pluripotent stem cells for modeling of X-linked dystonia-parkinsonism. , 2021, , 239-250.		0
31	Genotypeâ€“Phenotype Relations for Isolated Dystonia Genes: <scp>MDSGene</scp> Systematic Review. Movement Disorders, 2021, 36, 1086-1103.	3.9	74
32	Dystonia updates: definition, nomenclature, clinical classification, and etiology. Journal of Neural Transmission, 2021, 128, 395-404.	2.8	38
33	Neurocognitive profile of patients with X-linked dystonia-parkinsonism. Journal of Neural Transmission, 2021, 128, 671-678.	2.8	5
34	Linking Penetrance and Transcription in <scp>DYTâ€THAP1</scp>: Insights From a Human <scp>iPSC</scp>â€Derived Cortical Model. Movement Disorders, 2021, 36, 1381-1391.	3.9	14
35	Parkinsonâ€™s Disease Subtypes: Critical Appraisal and Recommendations. Journal of Parkinson's Disease, 2021, 11, 395-404.	2.8	56
36	Task matters - challenging the motor system allows distinguishing unaffected Parkin mutation carriers from mutation-free controls. Parkinsonism and Related Disorders, 2021, 86, 101-104.	2.2	6

#	Article	IF	Citations
37	Balancing scientific interests and the rights of participants in designing a recall by genotype study. European Journal of Human Genetics, 2021, 29, 1146-1157.	2.8	6
38	Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinsonâ€™s disease. Nature Genetics, 2021, 53, 787-793.	21.4	82
39	Exploring Uncharted Territory: Genetically Determined Sex Differences in Parkinson's Disease. Annals of Neurology, 2021, 90, 15-18.	5.3	3
40	Identifying genetic modifiers of age-associated penetrance in X-linked dystonia-parkinsonism. Nature Communications, 2021, 12, 3216.	12.8	34
41	Genomewide Association Studies of <scp>LRRK2</scp> Modifiers of Parkinson's Disease. Annals of Neurology, 2021, 90, 76-88.	5.3	30
42	Parkinson's disease. Lancet, The, 2021, 397, 2284-2303.	13.7	1,176
43	Brain Regional Differences in Hexanucleotide Repeat Length in X-Linked Dystonia-Parkinsonism Using Nanopore Sequencing. Neurology: Genetics, 2021, 7, e608.	1.9	18
44	Remembrance of Things Past: A Critical Step in Changing our Future. Annals of Neurology, 2021, 90, 521-523.	5.3	1
45	Frequency of Heterozygous Parkin (PRKN) Variants and Penetrance of Parkinson's Disease Risk Markers in the Population-Based CHRIS Cohort. Frontiers in Neurology, 2021, 12, 706145.	2.4	14
46	Genotypeâ€“Phenotype Relations in Primary Familial Brain Calcification: Systematic <scp>MDSGene</scp> Review. Movement Disorders, 2021, 36, 2468-2480.	3.9	35
47	<scp>COVID</scp>â€19 Vaccineâ€Associated Cerebral Venous Thrombosis in Germany. Annals of Neurology, 2021, 90, 627-639.	5.3	122
48	LIPAD (LRRK2/Luebeck International Parkinson's Disease) Study Protocol: Deep Phenotyping of an International Genetic Cohort. Frontiers in Neurology, 2021, 12, 710572.	2.4	3
49	Involuntary moaning in a Hispanic family with eight affected members. Parkinsonism and Related Disorders, 2021, 89, 206-208.	2.2	0
50	Nanopore Single-Molecule Sequencing for Mitochondrial DNA Methylation Analysis: Investigating Parkin-Associated Parkinsonism as a Proof of Concept. Frontiers in Aging Neuroscience, 2021, 13, 713084.	3.4	11
51	Complications of nasal and pharyngeal swabs: a relevant challenge of the COVID-19 pandemic?. European Respiratory Journal, 2021, 57, 2004004.	6.7	45
52	Dissection of TAF1 neuronal splicing and implications for neurodegeneration in X-linked dystonia-parkinsonism. Brain Communications, 2021, 3, fcab253.	3.3	8
53	The commercial genetic testing landscape for Parkinson's disease. Parkinsonism and Related Disorders, 2021, 92, 107-111.	2.2	16
54	Ceramide accumulation induces mitophagy and impairs Î²-oxidation in PINK1 deficiency. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	34

#	Article	IF	Citations
55	Validity and Prognostic Value of a Polygenic Risk Score for Parkinsonâ€™s Disease. Genes, 2021, 12, 1859.	2.4	15
56	Mitochondrial damage-associated inflammation highlights biomarkers in PRKN/PINK1 parkinsonism. Brain, 2020, 143, 3041-3051.	7.6	105
57	LifeTime and improving European healthcare through cell-based interceptive medicine. Nature, 2020, 587, 377-386.	27.8	108
58	Age at Onset of <scp>LRRK2</scp> p.<scp>Gly2019Ser</scp> Is Related to Environmental and Lifestyle Factors. Movement Disorders, 2020, 35, 1854-1858.	3.9	28
59	<scp>DNA</scp> Methylation as a Potential Molecular Mechanism in Xâ€linked Dystoniaâ€Parkinsonism. Movement Disorders, 2020, 35, 2220-2229.	3.9	7
60	Expanding Data Collection for the <scp>MDSGene</scp> Database: Xâ€linked Dystoniaâ€Parkinsonism as Use Case Example. Movement Disorders, 2020, 35, 1933-1938.	3.9	23
61	Clinical and Demographic Characteristics of Upper Limb Dystonia. Movement Disorders, 2020, 35, 2086-2090.	3.9	9
62	Stem Cells and Organoid Technology in Precision Medicine in Inflammation: Are We There Yet?. Frontiers in Immunology, 2020, 11, 573562.	4.8	13
63	Excess Lipin enzyme activity contributes to TOR1A recessive disease and DYT-TOR1A dystonia. Brain, 2020, 143, 1746-1765.	7.6	22
64	LRRK2 in Parkinson disease: challenges of clinical trials. Nature Reviews Neurology, 2020, 16, 97-107.	10.1	281
65	Rare Variants in Specific Lysosomal Genes Are Associated With Parkinson's Disease. Movement Disorders, 2020, 35, 1245-1248.	3.9	37
66	Risk of spread in adult-onset isolated focal dystonia: a prospective international cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 314-320.	1.9	50
67	Imaging gradual neurodegeneration in a basal ganglia model disease. Annals of Neurology, 2019, 86, 517-526.	5.3	23
68	Nomenclature of Genetically Determined Myoclonus Syndromes: Recommendations of the International Parkinson and Movement Disorder Society Task Force. Movement Disorders, 2019, 34, 1602-1613.	3.9	23
69	Risky behaviors and Parkinson disease. Neurology, 2019, 93, e1412-e1424.	1.1	18
70	An omics-based strategy using coenzyme Q10 in patients with Parkinsonâ€™s disease: concept evaluation in a double-blind randomized placebo-controlled parallel group trial. Neurological Research and Practice, 2019, 1, 31.	2.0	35
71	Mitochondrial DNA Deletions Discriminate Affected from Unaffected LRRK2 Mutation Carriers. Annals of Neurology, 2019, 86, 324-326.	5.3	17
72	Using global team science to identify genetic parkinson's disease worldwide. Annals of Neurology, 2019, 86, 153-157.	5.3	26

#	Article	IF	Citations
73	Discordance in monozygotic Parkinson's disease twins â€“ continuum or dichotomy?. Annals of Clinical and Translational Neurology, 2019, 6, 1102-1105.	3.7	4
74	A hexanucleotide repeat modifies expressivity of Xâ€linked dystonia parkinsonism. Annals of Neurology, 2019, 85, 812-822.	5.3	67
75	Will genotype drive treatment options?. Movement Disorders, 2019, 34, 1294-1299.	3.9	13
76	An integrated transcriptomics and proteomics analysis reveals functional endocytic dysregulation caused by mutations in LRRK2. Neurobiology of Disease, 2019, 127, 512-526.	4.4	58
77	Role of ANO3 mutations in dystonia: A large-scale mutational screening study. Parkinsonism and Related Disorders, 2019, 62, 196-200.	2.2	25
78	Utility and implications of exome sequencing in earlyâ€onset Parkinson's disease. Movement Disorders, 2019, 34, 133-137.	3.9	36
79	Association of Pallidal Neurostimulation and Outcome Predictors With X-linked Dystonia Parkinsonism. JAMA Neurology, 2019, 76, 211.	9.0	36
80	KLEIN, Christine: Luebeck/Germany. , 2019, , 95-98.		0
81	Dissecting the Causal Mechanism of X-Linked Dystonia-Parkinsonism by Integrating Genome and Transcriptome Assembly. Cell, 2018, 172, 897-909.e21.	28.9	163
82	Genetics of Parkinson disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 147, 211-227.	1.8	96
83	Genotypeâ€Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review. Movement Disorders, 2018, 33, 730-741.	3.9	215
84	High prevalence of olfactory dysfunction in cervical dystonia. Parkinsonism and Related Disorders, 2018, 53, 33-36.	2.2	12
85	WDR45 mutations may cause a MECP2 mutation-negative Rett syndrome phenotype. Neurology: Genetics, 2018, 4, e227.	1.9	14
86	The Basal Ganglia Striosomes Affect the Modulation of Conflicts by Subliminal Informationâ€"Evidence from X-Linked Dystonia Parkinsonism. Cerebral Cortex, 2018, 28, 2243-2252.	2.9	29
87	MDSGene: Closing Data Gaps in Genotype-Phenotype Correlations of Monogenic Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2018, 8, S25-S30.	2.8	33
88	Basal ganglia and cerebellar pathology in X-linked dystonia-parkinsonism. Brain, 2018, 141, 2995-3008.	7.6	41
89	Genotypeâ€phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review. Movement Disorders, 2018, 33, 1857-1870.	3.9	120
90	Genome editing in induced pluripotent stem cells rescues TAF1 levels in Xâ€linked dystoniaâ€parkinsonism. Movement Disorders, 2018, 33, 1108-1118.	3.9	35

#	Article	IF	Citations
91	The genetic nomenclature of recessive cerebellar ataxias. Movement Disorders, 2018, 33, 1056-1076.	3.9	61
92	Field synopsis and systematic meta-analyses of genetic association studies in isolated dystonia. Parkinsonism and Related Disorders, 2018, 57, 50-57.	2.2	9
93	Parkin and PINK1 mitigate STING-induced inflammation. Nature, 2018, 561, 258-262.	27.8	905
94	Striosomal dysfunction affects behavioral adaptation but not impulsivityâ€"Evidence from Xâ€linked dystoniaâ€parkinsonism. Movement Disorders, 2017, 32, 576-584.	3.9	37
95	Cardiolipin promotes electron transport between ubiquinone and complex I to rescue PINK1 deficiency. Journal of Cell Biology, 2017, 216, 695-708.	5.2	48
96	Munchausen syndrome by genetics: Next-generation challenges for clinicians. Neurology, 2017, 88, 1000-1001.	1.1	9
97	Sonographic alteration of substantia nigra is related to parkinsonism-predominant course of X-linked dystonia-parkinsonism. Parkinsonism and Related Disorders, 2017, 37, 43-49.	2.2	12
98	Update on the Genetics of Dystonia. Current Neurology and Neuroscience Reports, 2017, 17, 26.	4.2	98
99	Faithful SGCE imprinting in iPSC-derived cortical neurons: an endogenous cellular model of myoclonus-dystonia. Scientific Reports, 2017, 7, 41156.	3.3	18
100	Deep brain stimulation for dystonia: a novel perspective on the value of genetic testing. Journal of Neural Transmission, 2017, 124, 417-430.	2.8	68
101	Facial twitches in ADCY5 -associated disease - Myokymia or myoclonus? An electromyography study. Parkinsonism and Related Disorders, 2017, 40, 73-75.	2.2	16
102	Dysfunctions in striatal microstructure can enhance perceptual decision making through deficits in predictive coding. Brain Structure and Function, 2017, 222, 3807-3817.	2.3	12
103	Analysis of blood-based gene expression in idiopathic Parkinson disease. Neurology, 2017, 89, 1676-1683.	1.1	112
104	A novel, inâ€frame KMT2B deletion in a patient with apparently isolated, generalized dystonia. Movement Disorders, 2017, 32, 1495-1497.	3.9	18
105	Launching the movement disorders society genetic mutation database (MDSGene). Movement Disorders, 2016, 31, 607-609.	3.9	54
106	<scp>N</scp>omenclature of genetic movement disorders: <scp>R</scp>ecommendations of the international <scp>P</scp>arkinson and movement disorder society task force. Movement Disorders, 2016, 31, 436-457.	3.9	228
107	Evidence of TAF1 dysfunction in peripheral models of X-linked dystonia-parkinsonism. Cellular and Molecular Life Sciences, 2016, 73, 3205-3215.	5.4	37
108	Clinical and demographic characteristics related to onset site and spread of cervical dystonia. Movement Disorders, 2016, 31, 1874-1882.	3.9	39

#	Article	IF	Citations
109	The role of mutations in COL6A3 in isolated dystonia. Journal of Neurology, 2016, 263, 730-734.	3.6	15
110	A Missense Mutation in KCTD17 Causes Autosomal Dominant Myoclonus-Dystonia. American Journal of Human Genetics, 2015, 96, 938-947.	6.2	109
111	Short- and long-term outcome of chronic pallidal neurostimulation in monogenic isolated dystonia. Neurology, 2015, 84, 895-903.	1.1	117
112	MicroRNAs as biomarker of Parkinson disease?. Neurology, 2015, 84, 636-638.	1.1	10
113	New insights into the genetics of X-linked dystonia-parkinsonism (XDP, DYT3). European Journal of Human Genetics, 2015, 23, 1334-1340.	2.8	73
114	Primary Familial Brain Calcification With Known Gene Mutations. JAMA Neurology, 2015, 72, 460.	9.0	144
115	Woman With X-Linked Recessive Dystonia-Parkinsonism. JAMA Neurology, 2014, 71, 1177.	9.0	24
116	Mutations inGNAL. JAMA Neurology, 2014, 71, 490.	9.0	70
117	Mutations in VPS26A are not a frequent cause of Parkinson's disease. Neurobiology of Aging, 2014, 35, 1512.e1-1512.e2.	3.1	7
118	PINK1 Loss-of-Function Mutations Affect Mitochondrial Complex I Activity via NdufA10 Ubiquinone Uncoupling. Science, 2014, 344, 203-207.	12.6	300
119	Non-motor phenotype of dopa-responsive dystonia and quality of life assessment. Parkinsonism and Related Disorders, 2014, 20, 428-431.	2.2	28
120	The protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants. Neurobiology of Aging, 2014, 35, 266.e5-266.e14.	3.1	36
121	Child Neurology: PRRT2 -associated movement disorders and differential diagnoses. Neurology, 2014, 83, 1680-1683.	1.1	13
122	Unraveling Cellular Phenotypes of NovelTorsinA/TOR1AMutations. Human Mutation, 2014, 35, 1114-1122.	2.5	34
123	Translation of Oppenheim's 1911 paper on dystonia. Movement Disorders, 2013, 28, 851-862.	3.9	43
124	Phosphatase and Tensin Homolog (PTEN)-induced Putative Kinase 1 (PINK1)-dependent Ubiquitination of Endogenous Parkin Attenuates Mitophagy. Journal of Biological Chemistry, 2013, 288, 2223-2237.	3.4	199
125	Phenomenology and classification of dystonia: A consensus update. Movement Disorders, 2013, 28, 863-873.	3.9	1,754
126	Next-Generation Phenotyping Using theParkinExample. JAMA Neurology, 2013, 70, 1186.	9.0	99

#	Article	IF	Citations
127	Cohort Profile: A population-based cohort to study non-motor symptoms in parkinsonism (EPIPARK). International Journal of Epidemiology, 2013, 42, 128-128k.	1.9	32
128	Xâ€linked Dystoniaâ€Parkinsonism manifesting in a female patient due to atypical turner syndrome. Movement Disorders, 2013, 28, 675-678.	3.9	19
129	Fixing the broken system of genetic locus symbols. Neurology, 2012, 78, 1016-1024.	1.1	70
130	Identification and functional analysis of novel THAP1 mutations. European Journal of Human Genetics, 2012, 20, 171-175.	2.8	48
131	Genetics of Parkinson's Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a008888-a008888.	6.2	1,026
132	Translating new research findings into clinical practice. Nature Reviews Neurology, 2012, 8, 65-66.	10.1	2
133	Compensatory premotor activity during affective face processing in subclinical carriers of a single mutant Parkin allele. Brain, 2012, 135, 1128-1140.	7.6	54
134	Mitochondrial Parkin Recruitment Is Impaired in Neurons Derived from Mutant PINK1 Induced Pluripotent Stem Cells. Journal of Neuroscience, 2011, 31, 5970-5976.	3.6	348
135	From GWAS to clinical utility in Parkinson's disease. Lancet, The, 2011, 377, 613-614.	13.7	22
136	Translational Research in Neurology and Neuroscience 2011. Archives of Neurology, 2011, 68, 709-16.	4.5	12
137	The curious case of phenocopies in families with genetic Parkinson's disease. Movement Disorders, 2011, 26, 1793-1802.	3.9	40
138	Elucidating novel functions of TorsinA: Elimination of misfolded proteins from the endoplasmic reticulum. Movement Disorders, 2011, 26, 1974-1974.	3.9	0
139	The Wilson films â€" Huntington's Chorea. Movement Disorders, 2011, 26, 2464-2466.	3.9	0
140	Clinical neuroimaging and electrophysiological assessment of three DYT6 dystonia families. Movement Disorders, 2010, 25, 2405-2412.	3.9	38
141	Mutant Parkin Impairs Mitochondrial Function and Morphology in Human Fibroblasts. PLoS ONE, 2010, 5, e12962.	2.5	140
142	Effect of endogenous mutant and wild-type PINK1 on Parkin in fibroblasts from Parkinson disease patients. Human Molecular Genetics, 2010, 19, 3124-3137.	2.9	117
143	Mutations in THAP1 (DYT6) and generalised dystonia with prominent spasmodic dysphonia: a genetic screening study. Lancet Neurology, The, 2009, 8, 447-452.	10.2	194
144	Genetic association study of the Pâ€type ATPase ATP13A2 in lateâ€onset Parkinson's disease. Movement Disorders, 2009, 24, 429-433.	3.9	13

#	Article	IF	Citations
145	Hereditary parkinsonism: Parkinson disease lookâ€alikesâ€”An algorithm for clinicians to â€œPARKâ€• genes and beyond. Movement Disorders, 2009, 24, 2042-2058.	3.9	62
146	Frequency of heterozygous Parkin mutations in healthy subjects: Need for careful prospective follow-up examination of mutation carriers. Parkinsonism and Related Disorders, 2009, 15, 425-429.	2.2	37
147	Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurology, The, 2008, 7, 583-590.	10.2	1,340
148	The Gly2019Ser mutation in LRRK2is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Medicine, 2008, 6, 32.	5.5	102
149	Parkinson disease, 10 years after its genetic revolution: Multiple clues to a complex disorder. Neurology, 2007, 69, 2093-2104.	1.1	191
150	Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurology, The, 2007, 6, 652-662.	10.2	290
151	Biological effects of the PINK1 c.1366C>T mutation: implications in Parkinson disease pathogenesis. Neurogenetics, 2007, 8, 103-109.	1.4	35
152	LRRK2G2019S as a Cause of Parkinson's Disease in Ashkenazi Jews. New England Journal of Medicine, 2006, 354, 424-425.	27.0	661
153	Intrafamilial phenotypic and genetic heterogeneity of dystonia. Journal of the Neurological Sciences, 2006, 250, 92-96.	0.6	16
154	The genetics of Parkinson disease: implications for neurological care. Nature Clinical Practice Neurology, 2006, 2, 136-146.	2.5	153
155	PINK1, Parkin, and DJ-1 mutations in Italian patients with early-onset parkinsonism. European Journal of Human Genetics, 2005, 13, 1086-1093.	2.8	132